Mangiferin: A promising therapeutic agent for rheumatoid arthritis treatment

Medical Hypotheses

Volumn 83, Issue 5, 2014, Pages 570-574

  Luczkiewicz, P ^a   Kokotkiewicz, A ^a   Dampc, A ^a   Luczkiewicz, M ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANGIFERIN; MATRIX METALLOPROTEINASE; POLYPHENOL; PROSTAGLANDIN E2; TELOMERASE; XANTHONE; XANTHONE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARTILAGE CELL; CELL PROLIFERATION; CYTOTOXICITY; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; FIBROBLAST; FIBROBLAST LIKE SYNOVIAL CELL; HERBAL MEDICINE; HUMAN; INFLAMMATORY CELL; INTESTINE ABSORPTION; NONHUMAN; PHYTOTHERAPY; PROSTAGLANDIN SYNTHESIS; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; APOPTOSIS; ARTHRITIS, RHEUMATOID; BONE; CARTILAGE; CHEMISTRY; DRUG EFFECTS; INFLAMMATION; JOINT; METABOLISM; SYNOVIUM;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOPTOSIS; ARTHRITIS, RHEUMATOID; BONE AND BONES; CARTILAGE; CHONDROCYTES; FIBROBLASTS; HUMANS; INFLAMMATION; JOINTS; MATRIX METALLOPROTEINASES; NF-KAPPA B; POLYPHENOLS; SYNOVIAL MEMBRANE; XANTHONES;

EID: 84908252107     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.08.021     Document Type: Article

References (43)

1. Boissier M.C., Semerano L., Challal S., Saidenberg-Kermanac'h N., Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun 2012, 39:222-228.
2. Mor A., Abramson S.B., Pillinger M.H. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 2005, 115:118-128.
3. Shiozawa S., Tsumiyama K., Yoshida K., Hashiramoto A. Pathogenesis of joint destruction in rheumatoid arthritis. Arch Immunol Ther Exp 2011, 59:89-95.
4. Kobelt G., Woronoff A.S., Richard B., Peeters P., Sany J. Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR study. Joint Bone Spine 2008, 75:408-415.
5. Finckh A., Simard J.F., Gabay C., Guerne P.A. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006, 65:746-752.
6. Vyas A., Syeda K., Ahmad A., Padhye S., Sarkar F.H. Perspectives on medicinal properties of mangiferin. Mini-Rev Med Chem 2012, 12:412-425.
7. Matkowski A., Kuś P., Góralska E., Woźniak D. Mangiferin - a bioactive xanthonoid, not only from mango and not just antioxidant. Mini-Rev Med Chem 2013, 13:439-455.
8. Masibo M., He Q. Major mango polyphenols and their potential significance to human health. Compr Rev Food Sci Food Saf 2008, 7:309-319.
9. Kokotkiewicz A., Luczkiewicz M., Pawlowska J., et al. Isolation of xanthone and benzophenone derivatives from Cyclopia genistoides (L.) Vent. (honeybush) and their pro-apoptotic activity on synoviocytes from patients with rheumatoid arthritis. Fitoterapia 2013, 90:199-208.
10. Telang M., Dhulap S., Mandhare A., Hirwani R. Therapeutic and cosmetic applications of mangiferin: a patent review. Expert Opin Ther Pat 2013, 23:1561-1580.
11. Qu Z., Garcia C.H., O'Rourke L.M., Planck S.R., Kohli M., Rosenbaum J.T. Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Results of proliferating cell nuclear antigen/cyclin, c-myc, and nucleolar organizer region staining. Arthritis Rheum 1994, 37:212-220.
12. Lafyatis R., Remmers E.F., Roberts A.B., Yocum D.E., Sporn M.B., Wilder R.L. Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest 1989, 83:1267-1276.
13. Lefèvre S., Knedla A., Tennie C., et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 2009, 15:1414-1420.
14. Müller-Ladner U., Kriegsmann J., Franklin B.N., et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996, 149:1607-1615.
15. Shiozawa S., Shiozawa K., Fujita T. Morphologic observation in the early phase of the cartilage-pannus junction. Light and electron microscopic studies of active pannus. Arthritis Rheum 1983, 50:587-594.
16. Jacobs R.A., Perrett D., Axon J.M., Herbert K.E., Scott D.L. Rheumatoid synovial cell proliferation, transformation and fibronectin secretion in culture. Clin Exp Rheumatol 1995, 13:717-723.
17. Nykänen P., Helve T., Kankaanpää U., Larsen A. Characterization of the DNA-synthesizing cells in rheumatoid synovial tissue. Scand J Rheumatol 1978, 7:118-122.
18. Korb A., Pavenstädt H., Pap T. Cell death in rheumatoid arthritis. Apoptosis 2009, 14:447-454.
19. Okamoto T. The epigenetic alteration of synovial cell gene expression in rheumatoid arthritis and the roles on nuclear factor kappaB and Notch signaling pathways. Mod Rheumatol 2005, 15:79-86.
20. Yamasaki S., Kawakami A., Nakashima T., et al. Importance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cells. Ann Rheum Dis 2001, 60:678-684.
21. Burrage P.S., Mix K.S., Brinckerhoff C.E. Matrix metalloproteinases: role in arthritis. Front Biosci 2006, 11:529-543.
22. Okada Y. Matrix-degrading metalloproteinases and their roles in joint destruction. Mod Rheumatol 2000, 10:121-128.
23. Sweeney S.E., Firestein G.S. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol 2004, 36:372-378.
24. Morel J., Berenbaum F. Signal transduction pathways: new target for treating rheumatoid arthritis. Joint Bone Spine 2004, 71:503-510.
25. Simmonds R.E., Foxwell B.M. Signalling, inflammation and arthritis. NF-κB and its relevance to arthritis and inflammation. Rheumatology 2008, 47:584-590.
26. Kumar I.V., Paul B.N., Asthana R., Saxena A., Mehrotra S., Rajan G. Swertia chirayita mediated modulation of interleukin-1β, interleukin-6, interleukin-10, interferon-γ, and tumor necrosis factor-α in arthritic mice. Immunopharmacol Immunotoxicol 2003, 25:573-583.
27. Bhatia H.S., Candelario-Jalil E., de Oliveira A.C., Olajide O.A., Martínez-Sánchez G., Fiebich B.L. Mangiferin inhibits cyclooxygenase-2 expression and prostaglandin E2 production in activated rat microglial cells. Arch Biochem Biophys 2008, 477:253-258.
28. Cheng P., Peng Z.G., Yang J., Song S.J. The effect of mangiferin on telomerase activity and apoptosis in leukemic K562 cells. Zhongyaocai 2007, 30:306-309.
29. Garrido G., González D., Lemus Y., et al. In vivo and in vitro anti-inflammatory activity of Mangifera Indica L. extract (VIMANG). Pharmacol Res 2004, 50:143-149.
30. Shoji K., Tsubaki M., Yamazoe Y., et al. Mangiferin induces apoptosis by suppressing Bcl-xl and XIAP expression and nuclear entry of NF-κB in HL-60 cells. Arch Pharm Res 2011, 34:469-475.
31. Cho M.L., Cho C.S., Min S.Y., et al. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Arthritis Rheum 2002, 46:1202-1209.
32. Lioté F., Champy R., Moenner M., Boval-Biozard B., Badet J. Elevated angiogenin levels in synovial fluid from patients with inflammatory arthritis and secretion of angiogenin by cultured synovial fibroblasts. Clin Exp Immunol 2003, 132:163-168.
33. Jung J.S., Jung K., Kim D.H., Kim H.S. Selective inhibition of MMP-9 gene expression by mangiferin in PMA-stimulated human astroglioma cells: involvement of PI3K/Akt and MAPK signaling pathways. Pharmacol Res 2012, 66:95-103.
34. Joubert E., Gelderblom W.C.A., De Beer D. Phenolic contribution of South African herbal teas to a healthy diet. Nat Prod Commun 2009, 4:701-718.
35. Shaoying H., Fang W., Yingmei L., et al. Pharmacokinetic study of mangiferin in human plasma after oral administration. Food Chem 2012, 132:289-294.
36. Butoescu N., Jordan O., Doelker E. Intra-articular drug delivery systems for the treatment of rheumatic diseases: a review of the factors influencing their performance. Eur J Pharm Biopharm 2009, 73:205-218.
37. Henrotin Y., Lambert C., Couchourel D., Ripoll C., Chiotelli E. Nutraceuticals: do they represent a new era in the management of osteoarthritis? - a narrative review from the lessons taken with five products. Osteoarthr Cartil 2011, 19:1-21.
38. Choi S.I., Heo T.R., Min B.-H., Cui J.H., Choi B.H., Park S.R. Alleviation of osteoarthritis by calycosin-7-O-β-D-glucopyranoside (CG) isolated from Astragali radix (AR) in rabbit Osteoarthritis (OA) model. Osteoarthr Cartil 2007, 15:1086-1092.
39. Natarajan V., Krithica N., Madhan B., Sehgal P.K. Formulation and evaluation of quercetin polycaprolactone microspheres for the treatment of rheumatoid arthritis. J Pharm Sci 2011, 100:195-205.
40. Huh J.-E., Seo B.-K., Baek Y.-H., et al. Standardized butanol fraction of WIN-34B suppresses cartilage destruction via inhibited production of matrix metalloproteinase and inflammatory mediator in osteoarthritis human cartilage explants culture and chondrocytes. BMC Complement Altern Med 2012, 12:256.
41. Chalmers P.T., Sherman S.L., Raphael B.S., Su E.P. Rheumatoid synovectomy. Does the surgical approach matter?. Clin Orthop Relat Res 2011, 469:2062-2071.
42. Schaumburger J., Trum S., Anders S., et al. Chemical synovectomy with sodium morrhuate in the treatment of symptomatic recurrent knee joint effusion. Rheumatol Int 2012, 32:3113-3117.
43. Tak P.P., Gerlag D.M., Aupperle K.R., et al. Inhibitor of nuclear factor κB kinase β is a key regulator of synovial inflammation. Arthritis Rheum 2001, 44:1897-1907.